Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men
The DOI matches its Crossref record; 41 of the 43 references it cites were found in a registry or an index.
Abstract
Context: The impact of serum androgen manipulation on prostate tissue hormone levels in normal men is unknown. Studies of men with prostate cancer have suggested that prostatic androgens are preserved in the setting of castration. Tissue androgens might stimulate prostate growth, producing adverse clinical consequences. Objective: The objective of the study was to determine the effect of serum androgen manipulation on intraprostatic androgens in normal men. Design: Thirteen male volunteers ages 35–55 yr (prostate-specific antigen < 2.0 ng/ml; normal transrectal ultrasound) were randomly assigned to: 1) a long-acting GnRH-antagonist, acyline, every 2 wk; 2) acyline plus testosterone (T) gel (10 mg/d); or 3) placebo for 28 d. Serum hormones were assessed weekly. Prostate biopsies were obtained on d 28. Extracted androgens were measured by RIA, and immunohistochemistry for androgen-regulated proteins was performed. Results: The mean decrease in serum T was 94%, whereas prostatic T and dihydrotestosterone levels were 70 and 80% lower, respectively, in subjects receiving acyline alone compared with controls (P < 0.05). Despite this decrease in prostate androgens, there were no detectable differences in prostate epithelial proliferation, apoptosis, prostate-specific antigen, and androgen receptor expression. Conclusion: In this small study of healthy subjects, despite a 94% decrease in serum T with medical castration, intraprostatic T and dihydrotestosterone levels remained 20–30% of control values, and prostate cell proliferation, apoptosis, and androgen-regulated protein expression were unaffected. Our data highlight the importance of assessing tissue hormone levels. The source of persistent prostate androgens associated with medical castration and their potential role in supporting prostate metabolism deserves further study.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [38]
Citations
Cites
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082 · cited 2×
“known to be androgen-regulated (28, 29)] between the medically castrate group and the control subjects (Table 3).”
BackgroundSuicidal Tendencies: Apoptotic Cell Death by Caspase Family Proteinases
Wolf, B. B., & Green, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.29.20049 · Cited by 942
Roehrborn, C. G., Boyle, P., Nickel, J. C., Hoefner, K., & Andriole, G. (2002) · Urology · doi:10.1016/s0090-4295(02)01905-2 · Cited by 729
Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.
Thigpen, A. E., Silver, R. I., Guileyardo, J. M., Casey, M. L., McConnell, J. D., & Russell, D. W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116665 · Cited by 727 · cited 1×
“The prostate expresses high levels of type II 5 -reductase (1, 2) and enzymes involved in steroid metabolism (3, 4); therefore the endocrine milieu within the prostate may substantially differ from that of serum.”
BackgroundThe Androgen Axis in Recurrent Prostate Cancer
Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., Wilson, E. M., & French, F. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-1146-03 · Cited by 675 · cited 3×
“(15) who found a preservation of prostate T concentrations in hormone-refractory prostate cancer despite a minimum of 6 months of medical or surgical castration.”
BackgroundResultWolf, B. B., Schuler, M., Echeverri, F., & Green, D. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30651 · Cited by 487
Clark, R. V., Hermann, D. J., Cunningham, G. R., Wilson, T. H., Morrill, B. B., & Hobbs, S. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030330 · Cited by 467
Metabolism of anabolic androgenic steroids
Schänzer, W. (1996) · Clinical Chemistry · doi:10.1093/clinchem/42.7.1001 · Cited by 372 · cited 1×
“Although the half-life of serum T is in the order of hours (35), the half-life of tissue androgens is not known, and it is possible that longer periods of androgen ablation are required to see changes in prostate epithelial cell proliferation or apoptosis.”
BackgroundLabrie, F., Luu-The, V., Labrie, C., & Simard, J. (2001) · Frontiers in Neuroendocrinology · doi:10.1006/frne.2001.0216 · Cited by 366 · cited 2×
“Although it is possible that intraprostatic androgens arise from residual testicularderived serum androgens, the prostate has been shown to express, at least at the transcript level, all the enzymatic machinery required to convert adrenal precursors such as androstenedione, DHEA, and DHEA-S to DHT (3, 4), and increase…”
BackgroundPeters, C. A., & Walsh, P. C. (1987) · New England Journal of Medicine · doi:10.1056/nejm198709033171004 · Cited by 337 · cited 1×
“Very small but detectable changes in total and transitional zone volume have been observed with treatment using a potent 5 -reductase inhibitor as soon as 1 month in a very large cohort (36), although a previous small study of a GnRH agonist failed to detect changes in prostate size at 1 month (37).”
Background
Cited by
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536
Montgomery, R. B., Mostaghel, E. A., Vessella, R., Hess, D. L., Kalhorn, T. F., Higano, C. S., True, L. D., & Nelson, P. S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0249 · Cited by 1,419
Self-citationSun, S., Sprenger, C. C. T., Vessella, R. L., Haugk, K., Soriano, K., Mostaghel, E. A., Page, S. T., Coleman, I. M., Nguyen, H. M., Sun, H., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41824 · Cited by 748
Self-citationMostaghel, E. A., Marck, B. T., Plymate, S. R., Vessella, R. L., Balk, S., Matsumoto, A. M., Nelson, P. S., & Montgomery, R. B. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0728 · Cited by 588
“As shown inmultiple studies, suppression of serumandrogensdoesnot correlatewellwith suppression of tissue androgens in men undergoing androgen deprivation (4, 19, 20).”
Self-citationMostaghel, E. A., Page, S. T., Lin, D. W., Fazli, L., Coleman, I. M., True, L. D., Knudsen, B., Hess, D. L., Nelson, C. C., Matsumoto, A. M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3332 · Cited by 529
“Of note, at 1 month of castration, we did not observe significant changes in prostate size (5), or consistent changes in epithelial cell height (Supplementary Table S3); we also did not see any marked features of atrophy in the prostate epithelial cells, including those features that have been reported in studies of l…”
BackgroundMethodInfluentialSelf-citationMorgentaler, A., & Traish, A. M. (2009) · European Urology · doi:10.1016/j.eururo.2008.09.024 · Cited by 462
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433
“Normal prostate contains the enzymatic machinery to convert weak androgens produced by the adrenal glands, including androstenedione, dehydroepiandrosterone (DHEA), and DHEA-sulfate (DHEA-S, which circulates at high levels), into the physiological high affinity AR ligands testosterone and DHT, so prostatic testosteron…”
Self-citationAndrogen Signaling in Prostate Cancer
Dai, C., Heemers, H., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 406
“Residual concentrations of intratumoral DHT can remain at 10%–40% of pretreatment levels (Forti et al. 1989; Labrie et al. 1993; Page et al. 2006), even before the development of CRPC (Nishiyama et al. 2004).”
BackgroundMethodYuan, X., Cai, C., Chen, S., Chen, S., Yu, Z., & Balk, S. P. (2014) · Oncogene · doi:10.1038/onc.2013.235 · Cited by 370
Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels
Swerdloff, R. S., Dudley, R. E., Page, S. T., Wang, C., & Salameh, W. A. (2017) · Endocrine Reviews · doi:10.1210/er.2016-1067 · Cited by 237
Self-citationAndrogen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
Ryan, C. J., & Tindall, D. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2005 · Cited by 244
Modulation of Androgen Receptor Activation Function 2 by Testosterone and Dihydrotestosterone
Askew, E. B., Gampe, R. T., Stanley, T. B., Faggart, J. L., & Wilson, E. M. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703268200 · Cited by 210
Mechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
“Consistent with this intraprostatic synthesis of testosterone and DHT, healthy men treated with a GnRH antagonist had a 94% decline in serum testosterone, but only a 70–80% decline in prostate tissue levels of testosterone and DHT [61].”
BackgroundMitsiades, N., Sung, C. C., Schultz, N., Danila, D. C., He, B., Eedunuri, V. K., Fleisher, M., Sander, C., Sawyers, C. L., & Scher, H. I. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1335 · Cited by 197
“5% of baseline) and are no longer correlated with the serum level of testosterone, but with serum levels of the adrenal precursors DHEA andDHEA-S (12, 13, 42).”
Evolution of androgen receptor targeted therapy for advanced prostate cancer
Wong, Y. N. S., Ferraldeschi, R., Attard, G., & de Bono, J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.72 · Cited by 197
Buttigliero, C., Tucci, M., Bertaglia, V., Vignani, F., Bironzo, P., Di Maio, M., & Scagliotti, G. V. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.08.002 · Cited by 193
“AR binding with testosterone and DHT results in a conformational change of AR leading to a tight homodimeric binding to AREs.”
InfluentialAndrogens and androgen receptor signaling in prostate tumorigenesis
Zhou, Y., Bolton, E. C., & Jones, J. O. (2015) · Journal of Molecular Endocrinology · doi:10.1530/jme-14-0203 · Cited by 183
“A small study in medically castrated healthy men revealed that despite a 94% decrease in serum testosterone, intraprostatic testosterone and DHT levels remained within 20–30% of control values, and prostate cell proliferation, apoptosis, and androgen-regulated protein expression were unaffected (Page et al. 2006).”
BackgroundAndrogen action and metabolism in prostate cancer
Green, S. M., Mostaghel, E. A., & Nelson, P. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.046 · Cited by 181
“Furthermore, several studies have demonstrated that intratumoral androgens in CRPC tumors are maintained at levels sufficient to activate the AR signaling pathway (Geller et al., 1979; Mohler et al., 2004; Nishiyama et al., 2004; Page et al., 2006; Montgomery et al., 2008).”
BackgroundSelf-citationAn update on androgen deprivation therapy for prostate cancer
Sharifi, N., Gulley, J. L., & Dahut, W. L. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-10-0187 · Cited by 165
“Despite the w94% decline in serum testosterone with ADT, however, intraprostatic concentrations of testosterone and DHT decline by only 70–80% (Page et al. 2006).”
InfluentialTestosterone Therapy in Men With Untreated Prostate Cancer
Morgentaler, A., Lipshultz, L. I., Bennett, R., Sweeney, M., Avila, D., & Khera, M. (2011) · Journal of Urology · doi:10.1016/j.juro.2010.11.084 · Cited by 165
Intratumoral androgen biosynthesis in prostate cancer pathogenesis and response to therapy
Cai, C., & Balk, S. P. (2011) · Endocrine-Related Cancer · doi:10.1530/erc-10-0339 · Cited by 155
“In a recent study in healthy men, treatment for 1 month with a GnRH antagonist to suppress testicular androgen synthesis caused a 94% decline in serum testosterone, but only a 70–80% decline in prostate tissue testosterone and DHT (Page et al. 2006).”
BackgroundWright, J. L., Kwon, E. M., Ostrander, E. A., Montgomery, R. B., Lin, D. W., Vessella, R., Stanford, J. L., & Mostaghel, E. A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-1023 · Cited by 144
Self-citationThe current evidence on statin use and prostate cancer prevention: are we there yet?
Alfaqih, M. A., Allott, E. H., Hamilton, R. J., Freeman, M. R., & Freedland, S. J. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2016.199 · Cited by 138
Salameh, W. A., Goldman, M. M., Clarke, N. J., Reitz, R. E., & Caulfield, M. P. (2009) · Steroids · doi:10.1016/j.steroids.2009.11.004 · Cited by 140
Mostaghel, E. A., & Nelson, P. S. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.01.003 · Cited by 141
Self-citationMolecular Mechanisms of Castration-Resistant Prostate Cancer Progression
Dutt, S. S., & Gao, A. C. (2009) · Future Oncology · doi:10.2217/fon.09.117 · Cited by 155
“Intracrine androgen metabolism One highly significant recent development concerning CRPC is the discovery that levels of intracellular androgens and the expression of enzymes involved in androgen biosynthesis such as HSD3B1/2 and AKR1C1-3 are upregulated in CRPC [49–55].”
BackgroundEndocrine aspects of bone metastases
Hofbauer, L. C., Rachner, T. D., Coleman, R. E., & Jakob, F. J. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70203-1 · Cited by 132
Steroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
“Nonetheless, the depletion of intraprostatic androgens is incomplete with elimination of gonadal T, and approximately 20–30% of pretreatment DHT persists, even before the development of CRPC [56,57].”
BackgroundCastration-recurrent prostate cancer is not androgen-independent.
Mohler, J. L. (2008) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-69080-3_21 · Cited by 106
Interleukin-6 Regulates Androgen Synthesis in Prostate Cancer Cells
Chun, J. Y., Nadiminty, N., Dutt, S. S., Lou, W., Yang, J. C., Kung, H., Evans, C. P., & Gao, A. C. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0640 · Cited by 109
Androgen regulation of prostate cancer: Where are we now?
Corona, G., Baldi, E., & Maggi, M. (2011) · Journal of Endocrinological Investigation · doi:10.1007/bf03347072 · Cited by 108
Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Endocrinology · doi:10.1210/en.2013-1466 · Cited by 110
“Several groups have shown that, in the setting of gonadal testosterone depletion, prostatic tissues continue to retain physiologically significant concentrations of DHT (10, 11), which positively correlate with serum DHEA concentrations (10) and may therefore indicate the origins of the initial substrate utilized by p…”
BackgroundCastration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease
Mostaghel, E. A., Montgomery, B., & Nelson, P. S. (2009) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2009.03.016 · Cited by 101
Self-citationVis, A. N., & Schröder, F. H. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08695.x · Cited by 103
Targeted Androgen Pathway Suppression in Localized Prostate Cancer: A Pilot Study
Mostaghel, E. A., Nelson, P. S., Lange, P., Lin, D. W., Taplin, M. E., Balk, S., Ellis, W., Kantoff, P., Marck, B., Tamae, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.6431 · Cited by 85
“%) of 34 patients in the combined study cohorts had small-volume residual disease, defined as tumor volume 0.2 cm3 or less.19 In prior studies, achieving a nadir PSA below 0.2 ng/mL in 234 © 2013 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY response to androgen suppression was associated with…”
BackgroundInfluentialSelf-citationGat, Y., Gornish, M., Heiblum, M., & Joshua, S. (2008) · Andrologia · doi:10.1111/j.1439-0272.2008.00883.x · Cited by 87
“…drainage system were eliminated and, consequently, a rapid reduction in prostate volume and a regression of prostate symptoms took place. ª 2008 The Authors Journal Compilation ª 2008 Blackwell Publishing Ltd Æ Andrologia 40, 273–281 273 androgen receptors (AR) remain elevated (Page et al., 2006).”
BackgroundSteroid hormone synthetic pathways in prostate cancer.
Mostaghel, E. A. (2013) · PubMed · doi:10.3978/j.issn.2223-4683.2013.09.16 · Cited by 80
“Incomplete suppression of prostate tissue androgens by castration has been subsequently confirmed in numerous studies of short and long term castration therapy (8).”
BackgroundSelf-citationAndrogen–glucocorticoid interactions in the era of novel prostate cancer therapy
Narayanan, S., Srinivas, S., & Feldman, D. (2015) · Nature Reviews Urology · doi:10.1038/nrurol.2015.254 · Cited by 90
Evaul, K., Li, R., Papari-Zareei, M., Auchus, R. J., & Sharifi, N. (2010) · Endocrinology · doi:10.1210/en.2010-0138 · Cited by 81
Ishizaki, F., Nishiyama, T., Kawasaki, T., Miyashiro, Y., Hara, N., Takizawa, I., Naito, M., & Takahashi, K. (2013) · Scientific Reports · doi:10.1038/srep01528 · Cited by 90
Sowalsky, A. G., Ye, H., Bhasin, M., Allen, E. M. V., Loda, M. F., Lis, R. T., Montaser‐Kouhsari, L., Calagua, C., Ma, F., Russo, J. W., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0610 · Cited by 80
“Significantly, although treatment with a GnRH agonist decreases serum androgens, substantial levels persist in the prostate due to increased conversion of adrenal-derived DHEA to testosterone and DHT by normal prostate as well as by tumor cells (7, 8).”
BackgroundSelf-citationMinireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1007 · Cited by 76
“Nonetheless, studies assessing intraprostatic concentrations of T and DHT after the initiation of ADT have shown that androgens in benign prostate and prostate cancer are far from deplete (10, 11).”
Androgen Action in Prostate Cancer
Basu, S., & Tindall, D. J. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0044-4 · Cited by 91
“In fact, a recent publication has suggested that benign prostate tissue also contains levels of testicular androgens sufficient to activate the androgen receptor within 4 weeks after initiation of androgen deprivation therapy (Page et al. 2006).”
BackgroundPage, S. T., Lin, D. W., Mostaghel, E. A., Marck, B. T., Wright, J. L., Wu, J., Amory, J. K., Nelson, P. S., & Matsumoto, A. M. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-1865 · Cited by 76
Self-citationFunctional evidence implicating S100P in prostate cancer progression
Basu, G. D., Azorsa, D. O., Kiefer, J., Rojas, A. M., Tüzmen, Ş., Barrett, M. T., Trent, J. M., Kallioniemi, O., & Mousses, S. (2008) · International Journal of Cancer · doi:10.1002/ijc.23447 · Cited by 76
Mechanisms of Prostate Cancer Initiation and Progression
Knudsen, B. S., & Vasioukhin, V. I. (2010) · Advances in cancer research · doi:10.1016/b978-0-12-380890-5.00001-6 · Cited by 83
Hay, C. W., & McEwan, I. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032514 · Cited by 76
“Within the prostate gland, DHT is the dominant androgen having an approximately 6-fold higher concentration than testosterone [77].”
BackgroundDo Statins Affect Androgen Levels in Men? Results from the Boston Area Community Health Survey
Hall, S. A., Page, S. T., Travison, T. G., Montgomery, R. B., Link, C. L., & McKinlay, J. B. (2007) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-0306 · Cited by 69
“Several groups have shown that, in men treated with agents that modulate serum testosterone, tissue androgen levels are relatively unchanged (37-39).”
BackgroundSelf-citationKnuuttila, M., Yatkin, E., Kallio, J., Savolainen, S., Laajala, T. D., Aittokallio, T. A., Oksala, R., Häkkinen, M. R., Keski‐Rahkonen, P., Auriola, S. O. K., et al. (2014) · American Journal Of Pathology · doi:10.1016/j.ajpath.2014.04.010 · Cited by 74
Prostate Tissue Androgens: History and Current Clinical Relevance
Marks, L. S., Mostaghel, E. A., & Nelson, P. S. (2008) · Urology · doi:10.1016/j.urology.2008.03.033 · Cited by 69
Self-citationNambiar, D. K., Deep, G., Singh, R. P., Agarwal, C., & Agarwal, R. (2014) · Oncotarget · doi:10.18632/oncotarget.2488 · Cited by 69
“De novo androgen synthesis and sustained activation of AR signaling are the central events during PCA regrowth under low androgen conditions during hormonal ablation therapy [60-65].”
BackgroundTissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer
Heráček, J., Hampl, R., Martin, H., Luboslav, S., Jana, S., Jitka, K., Eis, V., Michael, U., & Mandys, V. (2007) · Steroids · doi:10.1016/j.steroids.2007.01.004 · Cited by 63
Androgen receptor: role and novel therapeutic prospects in prostate cancer
Taplin, M. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.9.1495 · Cited by 67
A potential paradox in prostate adenocarcinoma progression: Oestrogen as the initiating driver
Singh, P. B., Matanhelia, S. S., & Martin, F. L. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.02.051 · Cited by 66
Plymate, S. R., Haugk, K. H., Coleman, I. M., Woodke, L. B., Vessella, R. L., Nelson, P. S., Montgomery, B., Ludwig, D. L., & Wu, J. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0648 · Cited by 61
Self-citationAbiraterone in the treatment of metastatic castration-resistant prostate cancer
Mostaghel, E. A. (2014) · Cancer Management and Research · doi:10.2147/cmar.s39318 · Cited by 63
Self-citationModulation of AKR 1C2 by curcumin decreases testosterone production in prostate cancer
Ide, H., Lu, Y., Noguchi, T., Muto, S., Okada, H., Kawato, S., & Horie, S. (2018) · Cancer Science · doi:10.1111/cas.13517 · Cited by 55
Current topics in testosterone replacement of hypogonadal men
Nieschlag, E. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.09.008 · Cited by 57
The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52
The utility of prostate‐specific antigen in the management of advanced prostate cancer
Crawford, E. D., Bennett, C. L., Andriole, G. L., Garnick, M. B., & Petrylak, D. P. (2013) · British Journal of Urology · doi:10.1111/bju.12061 · Cited by 54
van der Sluis, T. M., Vis, A. N., van Moorselaar, R. J. A., Bui, H. N., Blankenstein, M. A., MEULEMAN, E. J. H., & Heijboer, A. C. (2011) · British Journal of Urology · doi:10.1111/j.1464-410x.2011.10651.x · Cited by 51
Nadiminty, N., & Gao, A. C. (2011) · World Journal of Urology · doi:10.1007/s00345-011-0771-3 · Cited by 55
“men [42].”
Androgens in prostate cancer: A tale that never ends
Hou, Z., Huang, S., & Li, Z. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.04.010 · Cited by 58
Testosterone and dihydrotestosterone levels in the transition zone correlate with prostate volume
Pejcic, T. P., Tosti, T. B., Tešić, Ž., Milković, B., Dragicevic, D. P., Kozomara, M., Čekerevac, M., & Dzamic, Z. M. (2017) · The Prostate · doi:10.1002/pros.23365 · Cited by 53
Prostate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.
Nandana, S., & Chung, L. W. K. (2014) · PubMed · Cited by 44
Dai, C. S., Chung, Y.-M., Kovac, E. Z., Zhu, Z., Li, J., Magi‐Galluzzi, C., Stephenson, A. J., Klein, E. A., & Sharifi, N. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1313 · Cited by 43
Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
Zhang, H., Yi, Z., Xing, Z., Sah, R. K., Hu, J., & Hu, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113521 · Cited by 46
Redefining hormone resistance in prostate cancer
Hoimes, C. J., & Kelly, W. K. (2009) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834009356433 · Cited by 47
“Intratumoral levels are often close enough to baseline controls where prostate cancer cell proliferation, apoptosis, and androgen-regulated protein expression, including PSA, are unaffected [Page et al. 2006].”
BackgroundGnRH agonists and the rapidly increasing use of combined androgen blockade in prostate cancer
Labrie, F. (2014) · Endocrine Related Cancer · doi:10.1530/erc-13-0165 · Cited by 43
“…of intraprostatic DHT have been more recently measured after castration, but the authors always indicate the importance of the remaining DHT for continuous cancer progression after castration and the role of intracrine androgen formation (Titus et al. 2005, Page et al. 2006, Arai et al. 2011).”
BackgroundReview of recent evidence in support of a role for statins in the prevention of prostate cancer
Hamilton, R. J., & Freedland, S. J. (2008) · Current Opinion in Urology · doi:10.1097/mou.0b013e3282f9b3cc · Cited by 40
Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
Gartrell, B. A., & Saad, F. (2015) · Therapeutic Advances in Urology · doi:10.1177/1756287215592288 · Cited by 40
“Abiraterone: rationale for use in mCRPC and mechanism of action Following suppression of serum testosterone with ADT, intraprostatic androgen levels remain at 20–30% of pre-ADT levels and are sufficient to maintain expression of androgen-responsive genes such as PSA and AR [Page et al. 2006; Mostaghel et al. 2007].”
BackgroundShi, L., Yan, Y., He, Y., Yan, B., Pan, Y., Orme, J. J., Zhang, J., Xu, W., Pang, J., & Huang, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3258 · Cited by 38
Sharifi, N., McPhaul, M. J., & Auchus, R. J. (2010) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181ff6bb8 · Cited by 39
“Paradigms such as these are responsible for the codification of pathways, which are readily found in textbooks, such as the pathway DHEA to AD to T to DHT.”
BackgroundInfluentialGacci, M., Corona, G., Apolone, G., Lanciotti, M., Tosi, N., Giancane, S., Masieri, L., Serni, S., Maggi, M., & Carini, M. (2010) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2010.4 · Cited by 34
Mechanisms of prostate cancer progression to androgen independence
McPhaul, M. J. (2008) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.02.006 · Cited by 40
The ubiquitin-proteasome system in prostate cancer and its transition to castration resistance
Voutsadakis, I. A., & Papandreou, C. N. (2010) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.03.013 · Cited by 34
“[58] Page ST, Lin DW, Mostaghel EA, et al.”
BackgroundResultMDV3100 for the treatment of prostate cancer
Mukherji, D., Pezaro, C. J., & Bono, J. S. D. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.651125 · Cited by 36
“Moreover, increasing evidence supports the hypothesis that prostate cancer cells have all the required cellular machinery to generate androgens and estrogens [14-18].”
BackgroundMaltais, R., Fournier, M.-A., & Poirier, D. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.06.003 · Cited by 35
Hong, M. Y., Seeram, N. P., Zhang, Y., & Heber, D. (2008) · Journal of Medicinal Food · doi:10.1089/jmf.2007.0702 · Cited by 33
“–39 There may be effects of statins on intracellular androgen synthesis in the PCa cell.”
New agents and strategies for the hormonal treatment of castration-resistant prostate cancer
Sharifi, N. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.494178 · Cited by 35
“However, despite a 94% fall in serum T, intraprostatic T and dihydrotestosterone (DHT) concentrations only decline by 70 -- 80% [8].”
BackgroundNovel drugs targeting the androgen receptor pathway in prostate cancer
Mateo, J., Smith, A. D., Ong, M., & Bono, J. S. D. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9472-2 · Cited by 34
“In effect, depletion of circulating testosterone cannot be equated to complete androgen ablation in the tumour microenvironment [30].”
Targeting sex steroid biosynthesis for breast and prostate cancer therapy
POUTANEN, M. H., Thulin, M. H., & Härkönen, P. L. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00609-y · Cited by 32
Effect of luteinizing hormone on the steroidogenic pathway in prostate cancer
Pinski, J., Xiong, S., Wang, Q., Stanczyk, F. Z., Hawes, D., & Liu, S. V. (2010) · The Prostate · doi:10.1002/pros.21305 · Cited by 32
“These intra-prostatic androgens in castrated men stimulate AR-mediated gene expression and protein synthesis [5,6].”
BackgroundChou, F.-J., Chen, Y., Chen, D., Niu, Y., Li, G., Keng, P., Yeh, S., & Chang, C. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2018.12.050 · Cited by 32
van der Sluis, T. M., Meuleman, E. J. H., van Moorselaar, R. J. A., Bui, H. N., Blankenstein, M. A., Heijboer, A. C., & Vis, A. N. (2012) · BJU International · doi:10.1111/j.1464-410x.2011.10652.x · Cited by 28
A Selective Androgen Receptor Modulator (OPK-88004) in Prostate Cancer Survivors: A Randomized Trial
Pencina, K. M., Burnett, A. L. “., Storer, T. W., Guo, W., Li, Z., Kibel, A. S., Huang, G. T.-W., Blouin, M., Berry, D. L., Basaria, S. S., et al. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab361 · Cited by 31
Thirumalai, A., Cooper, L. A., Rubinow, K. B., Amory, J. K., Lin, D. W., Wright, J. L., Marck, B. T., Matsumoto, A. M., & Page, S. T. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1483 · Cited by 29
“Based on previous data (22), the inclusion of 12 subjects per group afforded an 80% power to detect a 30% difference in intraprostatic DHT concentration between the lowest dose T group and the other groups receiving T gel ( 0.”
BackgroundMethodSelf-citationChoi, S. L., & Lee, A. (2011) · Drug Healthcare and Patient Safety · doi:10.2147/dhps.s24106 · Cited by 27
Role of Testosterone in Managing Advanced Prostate Cancer
Rove, K. O., Debruyne, F. M. J., Djavan, B., Gomella, L. G., Koul, H. K., Lucia, M. S., Petrylak, D. P., Shore, N. D., Stone, N. N., & Crawford, E. D. (2012) · Urology · doi:10.1016/j.urology.2012.05.006 · Cited by 32
“There are, owever, persistent levels of testosterone (20%) and HT (30%) within the prostate after LHRH agonist herapy, derived from the intraprostatic conversion of drenal steroids.(10) The clinical effect of these residual ntraprostatic androgens on PCa progression remains unlear.”
BackgroundNew Hormonal Therapies for Castration-Resistant Prostate Cancer
Mostaghel, E. A., & Plymate, S. R. (2011) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2011.05.013 · Cited by 28
Self-citationLoughlin, K. R. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.05.023 · Cited by 27
“[9] In this small study of healthy volunteers, despite a 94% drop in serum T following medical castration, intraprostatic T, and DHT levels remained at 20% to 30% of control values.”
BackgroundLabrie, F. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.05.012 · Cited by 26
Rationale for statins in the chemoprevention of prostate cancer
Hamilton, R. J., & Freedland, S. J. (2008) · Current Urology Reports · doi:10.1007/s11934-008-0034-z · Cited by 26
The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy
Xu, G., Dai, G., Huang, Z., Guan, Q., Du, C., & Xu, X. (2024) · Research and Reports in Urology · doi:10.2147/rru.s477396 · Cited by 48
“…reduces 70% of prostatic T and 80% of DHT that have no effect on prostate cell proliferation, apoptosis, and androgen-regulated protein expression, 30 suggesting that the physiological levels of intraprostatic T and DHT may not be required for prostate cell proliferation in healthy prostates or…”
BackgroundTargeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review
Anantharaman, A., & Friedlander, T. W. (2015) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2015.11.003 · Cited by 27
“The men receiving ADT showed 94% reduction in serum testosterone, but only a 70% and 80% respective decrease in intraprostatic levels of testosterone and dihydrotestosterone (DHT) [22].”
BackgroundInfluentialMarcelli, M., & Mediwala, S. N. (2020) · Journal of Investigative Medicine · doi:10.1136/jim-2019-001233 · Cited by 25
Harshman, L. C., & Taplin, M. (2013) · Advances in Therapy · doi:10.1007/s12325-013-0050-3 · Cited by 27
“induction of castrate levels of serum testosterone with gonadotropin-releasing hormone (GnRH) agonists, intraprostatic tissue androgen levels may only decline by approximately 30%, leaving sufficient ligand to stimulate the AR [24].”
BackgroundPathak, A. S., Pacificar, J. S., Shapiro, C. E., & Williams, S. G. (2007) · The Journal of Urology · doi:10.1016/j.juro.2007.01.157 · Cited by 23
Androgens and prostate disease
Page, S., & Cooper, L. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122361 · Cited by 30
“In the healthy prostate, treatment for one month with a potent GnRH antagonist (93) decreased”
BackgroundSelf-citation
Metadata
- Authors
- Page, S. T., Lin, D. W., Mostaghel, E. A., Hess, D. L., True, L. D., Amory, J. K., Nelson, P. S., Matsumoto, A. M., & Bremner, W. J.
- Affiliations
- VA Puget Sound Health Care System (US)
- Departments of Medicine (S.T.P., E.A.M., J.K.A., P.S.N., A.M.M., W.J.B.), Seattle, Washington 98195
- Oregon National Primate Research Center (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Page, Stephanie T.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2006-10-01
- Volume
- 91
- Issue
- 10
- Pages
- 3850-3856
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2155279970
- Cited by
- 229
- References
- 43
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 9 · 2022: 6 · 2021: 7 · 2020: 6 · 2019: 8 · 2018: 5 · 2017: 10 · 2016: 8 · 2015: 11 · 2014: 19 · 2013: 21 · 2012: 19
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Veterans Affairs
- National Institutes of Health (5u54hd012629-31)
- National Institute on Aging (K23AG027238)
- National Cancer Institute (CA 97186, P50CA097186)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK065204, DK65204, DK 65083, K23DK065083)
- National Center for Research Resources (RR-00163.)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54HD042454, U54-HD-12629)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- medical castration, GnRH antagonist, acyline, testosterone gel, dihydrotestosterone, prostate-specific antigen, androgen receptor, apoptosis, healthy men
- MeSH terms
- Adult, Androgens, Follicle Stimulating Hormone, Humans, Immunohistochemistry, Luteinizing Hormone, Male, Middle Aged, Orchiectomy, Prostate, Dihydrotestosterone, Testosterone, Prostate-Specific Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.